Android app on Google Play

Jefferies Starts Arrowhead Research (ARWR) at Buy

December 18, 2013 6:41 AM EST Send to a Friend
Get Alerts ARWR Hot Sheet
Price: $14.77 -2.83%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 5
Trade ARWR Now!
Join SI Premium – FREE
Jefferies initiates coverage on Arrowhead Research (NASDAQ: ARWR) with a Buy. PT $15.00.

Analyst Thomas Wei comments: "We see ARWR's differentiated RNAi platform as its key value driver. As lead program, ARC-520 for hepatitis B, progresses, it should provide confidence around safety and mechanistic validation for the technology, even if HBV cures are not achieved. We expect expansion into liver targeted orphan diseases should create significant value."

NOTE: In Oct., Jefferies acted as Lead Placement Agent in the private offering of ARWR common shares and convertible preferred stock.

For an analyst ratings summary and ratings history on Arrowhead Research click here. For more ratings news on Arrowhead Research click here.

Shares of Arrowhead Research closed at $8.75 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Jefferies & Co, Thomas Wei

Add Your Comment